Posted by Michael Wonder on 24 May 2017
NICE nod for psoriatic arthritis drugs Cimzia and Cosentyx
24 May 2017 - Cost regulators for the NHS in England and Wales are recommending UCB's Cimzia and Novartis' Cosentyx as treatment options for adults with active psoriatic arthritis.
In final guidance, NICE has backed use of Cimzia (certolizumab pegol) alone or in combination with methotrexate if the person has had a TNF-alpha inhibitor but their disease has stopped responding after the first 12 weeks.
Cosentyx (secukinumab) is recommended alone, or in combination with methotrexate, in the same circumstances, and also if TNF-alpha inhibitors are contraindicated but would otherwise be considered.
